The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
Mok, T. S., Wu, Y.-L., Ahn, M.-J., Garassino, M. C., Kim, H. R., Ramalingam, S. S., Shepherd, F. A., He, Y., Akamatsu, H., Theelen, W. S. M. E., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612674 · Cited by 3,379
Gainor, J. F., Shaw, A. T., Sequist, L. V., Fu, X., Azzoli, C. G., Piotrowska, Z., Huynh, T. G., Zhao, L., Fulton, L., Schultz, K. R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3101 · Cited by 1,250
Chen, L., Gibbons, D. L., Goswami, S., Cortez, M. A., Ahn, Y.-H., Byers, L. A., Zhang, X., Yi, X., Dwyer, D., Lin, W., et al. (2014) · Nature Communications · doi:10.1038/ncomms6241 · Cited by 966
Cited by
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Duma, N., Santana-Davila, R., & Molina, J. R. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.01.013 · Cited by 2,184
Wu, S.-G., & Shih, J.-Y. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0777-1 · Cited by 778
Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Remon, J., Steuer, C. E., Ramalingam, S. S., & Felip, E. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx704 · Cited by 322
Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
Jiang, Y., & Zhan, H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.013 · Cited by 319
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Peng, S., Wang, R., Zhang, X., Ma, Y., Zhong, L., Li, K., Nishiyama, A., Arai, S., Yano, S., & Wang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1073-4 · Cited by 310
Metadata
- Authors
- Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., Mitsudomi, T., Nishio, K., & Nakagawa, K.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-07
- Volume
- 28
- Issue
- 7
- Pages
- 1532-1539
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2606022415
- Cited by
- 296
- References
- 19
- FWCI
- 26.93
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. https://app.cochat.ai/papers/10.1093/annonc/mdx183
- The paper
- Haratani, K., Hayashi, H., Tanaka, T., Kaneda, H., Togashi, Y., Sakai, K., Hayashi, K., Tomida, S., Chiba, Y., Yonesaka, K., Nonagase, Y., Takahama, T., Tanizaki, J., Tanaka, K., Yoshida, T., Tanimura, K., Takeda, M., Yoshioka, H., Ishida, T., . . . Nakagawa, K. (2017). Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment. Annals of Oncology. https://doi.org/10.1093/annonc/mdx183
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.